Menu
HARNESSING THE BENEFIT OF NOVEL CAR-T THERAPY
Pepromene Bio Inc

PEPROMENE BIO INC
PeproMene Bio Inc. is a virtual, privately funded biotech company located Irvine, CA. We are developing novel immune-oncology therapies such as BAFF-R CAR-T therapy based on the novel antibodies. The BAFF-R CAR-T therapy program which was discovered and developed from Dr. Larry Kwak’s lab at MD Anderson and City of Hope was successfully licensed in from City of Hope, Duarte CA, in April 2017...
Read More

Management Scientific Advisory Board

SCIENCE
BAFF (B cell activating factor), a soluble cytokine expressed by B cells is known for their proliferation and differentiation. Particularly BAFF-R (B cell activating factor receptor) is an excellent potential target for B-cell cancers not only the specificity on the BAFF, but also for its expression level by lymphoproliferative as well as leukemia-proliferative disorders. Successful discovery of anti-BAFF-R mAbs humanized C55 and C90 mAbs demonstrate high binding affinity to various NHLs. The BAFF-R CAR-T was constructed based on them as scFv using 2nd generation signaling domains... Read More

BAFF R CAR-T Cell Pipelines

CONTACT
PeproMene Bio. Inc
15375 Barranca Pkwy. Suite A211
Irvine, CA 92618

T: 949-564-4085
E: steve@pepromenebio.com
COPYRIGHT © 2017-2018 PeproMene Bio. Inc. ALL RIGHTS RESERVED